Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency

Blood Cancer Journal, Published online: 28 June 2023; doi:10.1038/s41408-023-00865-zOutcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency

Source: Blood Cancer Journal - June 28, 2023 Category: Hematology Authors: Gian Matteo Rigolin Pier Paolo Olimpieri Valentina Summa Simone Celant Lydia Scarf ò Lucia Tognolo Maria Pia Ballardini Antonio Urso Mariarosaria Sessa Silvia Gambara Francesca Cura Monica Fortini Paolo Ghia Antonio Cuneo Pierluigi Russo Source Type: research